Insight Molecular Diagnostics Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Insight Molecular Diagnostics Inc. (IMDX) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$11.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$11.26M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.29M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$22.95M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$10.85M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$50.22M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$60.66M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$24.86M.
- Insight Molecular Diagnostics Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2022 was -$18.61M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.26M 10-Q · filed 2026-08-10 | -$15.55M 10-Q · filed 2026-08-10 | -$38.51M derived: sum of 3 quarters · filed 2026-08-10 | -$49.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$4.29M 10-Q · filed 2026-05-13 | -$27.25M derived: sum of 2 quarters · filed 2026-05-13 | -$38.10M derived: sum of 3 quarters · filed 2026-05-13 | -$47.84M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$22.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$33.81M derived: sum of 2 quarters · filed 2026-03-26 | -$43.55M derived: sum of 3 quarters · filed 2026-08-10 | -$50.22M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$10.85M 10-Q · filed 2025-11-10 | -$20.60M derived: sum of 2 quarters · filed 2026-08-10 | -$27.27M 10-Q · filed 2025-11-10 | -$60.78M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$9.74M 10-Q · filed 2026-08-10 | -$16.41M 10-Q · filed 2026-08-10 | -$49.92M derived: sum of 3 quarters · filed 2026-08-10 | -$63.42M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$6.67M 10-Q · filed 2026-05-13 | -$40.18M derived: sum of 2 quarters · filed 2026-05-13 | -$53.67M derived: sum of 3 quarters · filed 2026-05-13 | -$58.20M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$33.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$47.00M derived: sum of 2 quarters · filed 2026-03-26 | -$51.53M derived: sum of 3 quarters · filed 2026-03-26 | -$60.66M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$13.49M 10-Q · filed 2025-11-10 | -$18.02M derived: sum of 2 quarters · filed 2025-11-10 | -$27.15M 10-Q · filed 2025-11-10 | -$43.14M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$4.53M 10-Q · filed 2025-08-11 | -$13.66M 10-Q · filed 2025-08-11 | -$29.65M derived: sum of 3 quarters · filed 2025-08-11 | -$36.14M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$9.13M 10-Q · filed 2025-05-12 | -$25.12M derived: sum of 2 quarters · filed 2025-05-12 | -$31.61M derived: sum of 3 quarters · filed 2025-05-12 | -$39.94M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$15.99M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$22.48M derived: sum of 2 quarters · filed 2025-03-24 | -$30.81M derived: sum of 3 quarters · filed 2025-03-24 | -$24.86M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$6.49M 10-Q · filed 2024-11-12 | -$14.82M derived: sum of 2 quarters · filed 2024-11-12 | -$8.86M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$8.33M 10-Q · filed 2024-08-08 | -$2.37M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $5.96M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$18.61M 10-K · filed 2023-04-12 | |||
| 2022-06-30 | -$1.36M 10-Q · filed 2023-08-10 | -$4.78M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$3.41M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$43.61M 10-K · filed 2023-04-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |